

CURRICULUM VITAE



PERSONAL INFORMATION

Name	MAURIZIO MARTINI
Address	Via Palombara, 3, 01033, Civita Castellana (VT) Largo A. Gemelli 8, 00168, Rome, Italy
Work address	Institute of Pathology, Largo A. Gemelli 8, 00168, Rome, Italy
Telephone	Catholic University of Sacred Heart
	06/30154433
Fax	06/30157008
E-mail	<u>maurizio.martini@unicatt.it</u> ; <u>maurizio.martini@policlinicogemelli.it</u> <u>maurizio.martini@unicamillus.org</u>
Nationality	Italiana
Birth date	04/03/1971; CF. MRTMRZ71C04H501Q

EDUCATION

1997: M.D. Medicine Doctor with honor, Faculty of Medicine, Catholic University of Sacred Heart, Rome

2002: Specialist in Pathology with honor, Faculty of Medicine, Catholic University of Sacred Heart, Rome

2007: Ph.D. Research Doctorate in "Hemopathology", Catholic University of Sacred Heart, Rome

From 2007 to 2011: Post-doct, Molecular Pathology laboratory, Research project: Molecular characterization of chronic myeloproliferative diseases. Supervisor: Prof. Larocca Luigi Maria

2011: Assistant Professor in Pathology, (Anatomia Patologica, Scientific Sector MED/08)

2012: Scientific Director of the Molecular Pathology Laboratory, Catholic University of Sacred Heart, Rome (Servizio di Istopatologia e Citodiagnosi, Ospedale Agostino Gemelli, Roma)

2014: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2014: Assistant Medical Director, (Servizio di Istopatologia e Citodiagnosi, Ospedale Agostino Gemelli, Roma)

2016: Director of the Molecular pathology laboratories.

2018: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2020: National Scientific Qualification for Full Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2021: Associate Professor in Pathology, Catholic University of Sacred Heart, Rome

POSITION HELD

Assistant Professor in Pathology, Assistant Medical Director in Pathology, Scientific Director of Molecular Pathology Laboratory

MOTHER TONGUE
OTHER LANGUAGES

ITALIAN
ENGLISH (READING SKILL: VERY GOOD; WRITING SKILL: VERY GOOD; VERBAL SKILL: GOOD)

HONOURS

From 2001 to 2002: Annual grant for young researcher, Faculty of Medicine, Catholic University of Sacred Heart

2003: Annual grant by Italian Association for Cancer Research (AIRC). Research project: Molecular characterization of chronic myeloproliferative diseases.

From 2005 to 2010: Annual grant by Faculty of Medical Biotechnology, Catholic University of Sacred Heart. Research project: Biotechnological applications in Pathology. Supervisor: Prof. Larocca Luigi Maria.

From 2011 to 2012: Annual grant by Faculty of Medicine, Catholic University of Sacred Heart. Linea D1.

2014-18: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2021: Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

RESEARCH INTERESTS

Hematopathology: Normal and pathological hematopoiesis; chronic myeloproliferative diseases; acute promyelocytic leukaemia; lymphomagenesis in immunocompetent and immunocompromised (HIV) patients; infection (EBV-HIV) and lymphomagenesis; chronic lymphocytic leukemia, Richter syndrome; Hodgkin disease; non-Hodgkin lymphoma; large B cell lymphoma; Primary cerebral lymphomatoid granulomatosis; Primary central nervous system lymphoma; healthy and pathological hematopoietic niche; circulating hematopoietic and endothelial precursors; hematopoietic cancer stem cell; apoptosis and hematopoiesis.

Glial and central nervous system cancer: Glioblastoma pathogenesis; Glioblastoma cancer stem cell; Angiogenesis in Glioblastoma, Cancer stem cell transdifferentiation, Targeted therapy in Glioblastoma; autophagic programmed cell death and glioblastoma; genome characterization of glioblastoma subtypes; recurrent glioblastoma; chordoma; anaplastic ependymoma.

Gastrointestinal tumor: colorectal cancer pathogenesis; targeted therapy in colorectal cancer; inflammatory bowel disease and cancer; gastrointestinal stromal tumor; hereditary gastrointestinal tumor syndrome; gastrointestinal cancer stem cell; neoangiogenesis in colorectal cancer; secondary resistance in colorectal cancer targeted therapy.

Lung cancer: targeted therapy and non-small cell lung carcinoma; neuroendocrine cancer.

Thyroid cancer: papillary cancer; follicular lesion of thyroid; medullary thyroid cancer.

Genitourinary cancer: endometrial carcinoma and endometriosis; prostate cancer and inflammation; seminoma and germinal cell tumor.

University teaching courses

Dr. Martini teaches in several university courses in the Medical and Dentistry Faculties, Catholic University of Sacred Heart, Faculty of Medical Biotechnology, Catholic University of Sacred Heart, Pathology postgraduate school, Hematology and Urology postgraduate school, Doctoral school of Oncology, University masters (first and second level).

Reviewer Activity

Scientific Journal: Journal of Clinical Oncology, Blood, New England Journal of Medicine, Journal of Experimental & Clinical Cancer Research, Haematologica, Neoplasia, International Journal of Cancer, Oncotarget, Oncogene, Modern Pathology, American Journal of Surgical Pathology, Mediterranean Journal of Hematology and infectious Diseases, Pediatric Blood & Cancer, International Journal of Molecular Sciences.

Member of the editorial Board: BMC Cancer, IJMM, Cancers, Diagnostics, MJHID.

National and International Funding and Grant Associations: Italian Miur and Firc; Anvur Cineca; Cancer Research UK, Arc France, Fondazione delle Scienze della Repubblica Ceca.

Bibliometric indexes

Dr. Martini is the author of 222 scientific publications cited by PubMed.org:

a) **first name** in 25

b) **second name** in 31

c) **seniorship** in 6,

Dr. Martini has a total *IMPACT FACTOR* greater than 800 e as first name greater than 150 (average as first name, IF 6,7).

1) SciVerse Scopus 15/07/2021

H. index 39

Documents selected: 22

Total citations: 4478

Academic age: 20.0 year/s

2) ISI Web of Knowledge, Web of Science 15/07/2021

Results found: 214

Sum of the Times Cited: 2832

Average Citations per Item: 11.5

h-index: **38**

3) Harzing's Publish or Perish 15/07/2021

Papers/Author	Hi, annual	H index	G index	Cites/Author	hI norm
25.08	0.71	47	55	32.64	10

4) Dr. Martini has become part of the best Italian scientists from June 2015, with an H-index of 46 in VIA Academy, <http://www.topitalianscientists.org>

SCIENTIFIC PUBLICATIONS:

1. Servidei T, Meco D, **Martini M**, Battaglia A, Granitto A, Buzzonetti A, Babini G, Massimi L, Tamburrini G, Scambia G, Ruggiero A, Riccardi R. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. *Int J Mol Sci.* 2021 Feb 13;22(4):1877. doi: 10.3390/ijms22041877. PMID: 33668642; PMCID: PMC7918371.
2. Straccia P, **Martini M**, Pierconti F. Pericardial metastasis from alveolar rhabdomyosarcoma: A case report. *Diagn Cytopathol.* 2021 Feb 9. Doi 10.1002/dc.24717. Epub ahead of print. PMID: 33560576.
3. Ferrara MG*, **Martini M***, D'Argento E, Forcella C, Vita E, Di Noia V, Sperduti I, Bilotta M, Ribelli M, Damiano P, Cannella A, Stefani A, Pilotto S, Carbone C, Piro G, Milella M, Tortora G, Bria E. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. *Clin Lung Cancer.* 2021 Feb 5:S1525-7304(20)30351-X. doi: 10.1016/j.clcc.2020.12.008. Epub ahead of print. PMID: 33558194.
4. Schino M, Fiorentino V, Rossi E, Betti S, Di Cecca M, Ranucci V, Chiusolo P, **Martini M***, De Stefano V*, Larocca LM. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. *Haematologica.* 2020 Nov 19. doi: 10.3324/haematol.2020.264143. Epub ahead of print. PMID: 33543865.
5. Tassinari V, Cesarini V, Tomaselli S, Ianniello Z, Silvestris DA, Ginistrelli LC, **Martini M**, De Angelis B, De Luca G, Vitiani LR, Fatica A, Locatelli F, Gallo A. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. *Genome Biol.* 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9. PMID: 33509238; PMCID: PMC7842030.
6. Melotti L, Meco D, Battaglia A, Buzzonetti A, **Martini M**, Ruggiero A, Scambia G, Riccardi R. Targeting the mitogen-activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low-grade glioma cells. *Oncol Rep.* 2020 Nov 25. doi: 10.3892/or.2020.7867. Epub ahead of print. PMID: 33416182.
7. Fiorentino V*, **Martini M***, Dell'Aquila M, Musarra T, Orticelli E, Larocca LM, Rossi E, Totaro A, Pinto F, Lenci N, Di Paola V, Manfredi R, Bassi PF, Pierconti F. Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. *Diagnostics (Basel).* 2020 Dec 23;11(1):10. doi: 10.3390/diagnostics11010010. PMID: 33374618; PMCID: PMC7822416.
8. Presacco S, Agnes AL, Magalini S, Carbone A, **Martini M**, Agnes A. Bleeding "sarcomatosis" as a rare presentation of vascular graft-related angiosarcoma: case report and review of the literature. *BMC Surg.* 2020 Nov 20;20(1):291. doi: 10.1186/s12893-020-00966-7. PMID: 33218319; PMCID: PMC7678180.
9. Lenci N, Francesco P, Scarciglia E, Fiorentino V, Schino M, Palermo G, Racioppi M, Bassi P, **Martini M**. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process. *Med Mol Morphol.* 2020 Nov 11. doi: 10.1007/s00795-020-00269-z. Epub ahead of print. PMID: 33175195.
10. Miele L, Alberelli MA, **Martini M**, Liguori A, Marrone G, Cocomazzi A, Vecchio FM, Landolfi R, Gasbarrini A, Grieco A, De Candia E. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. *Transl Res.* 2020 Nov 7:S1931-5244(20)30255-3. doi: 10.1016/j.trsl.2020.11.003. Epub ahead of print. PMID: 33171266.
11. Pierconti F, **Martini M**, Fiorentino V, Cenci T, Capodimonti S, Straccia P, Sacco E, Pugliese D, Cindolo L, Larocca LM, Bassi PF. The combination cytology/epicheck test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? *Urol Oncol.* 2021 Feb;39(2):131.e17-131.e21. doi: 10.1016/j.urolonc.2020.06.018. Epub 2020 Aug 7. PMID: 32773233.
12. Straccia P, Rossi ED, **Martini M**, Mulè A, Cianfrini F, Curatolo M, Cancellieri A, Brunelli C, Zannoni GF, Fadda G. Description of a new biosafe procedure for cytological specimens from patients with COVID-19 processed by liquid-based preparations. *Cancer Cytopathol.* 2020 Dec;128(12):905-909. doi: 10.1002/cncy.22341. Epub 2020 Aug 7. PMID: 32767745; PMCID: PMC7436212.
13. Antonelli R, Jiménez C, Riley M, Servidei T, Riccardi R, Soriano A, Roma J, Martínez-Saez E, **Martini M**, Ruggiero A, Moreno L, Sánchez de Toledo J, Gallego S, Bové J, Hooker JM, Segura MF. CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. *Cancers (Basel).* 2020 Jul 16;12(7):1922. doi: 10.3390/cancers12071922. PMID: 32708733; PMCID: PMC7409080.
14. Marano M, Brunelli C, De Marco C, **Martini M**, Quattrocchi CC, Lauriola L, Di Lazzaro V. Neuroimages and Neuropathology of a Stroke-Like Cerebral Lymphomatoid Granulomatosis. *Can J Neurol Sci.* 2021 Jan;48(1):114-115. doi: 10.1017/cjn.2020.133. Epub 2020 Jul 6. PMID: 32624028.
15. Girolami I, Pantanowitz L, Munari E, **Martini M**, Nocini R, Bisi N, Molteni G, Marchioni D, Ghimenton C, Brunelli M, Eccher A. Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis. *Head Neck.* 2020 Oct;42(10):3018-3030. doi: 10.1002/hed.26339. Epub 2020 Jun 22. PMID: 32567746.
16. D'alessandris QG, **Martini M**, Cenci T, Di Bonaventura R, Lauretti L, Stumpo V, Olivi A, Larocca LM, Pallini R, Montano N. Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach. *J Neurosurg Sci.* 2020 Jun 17. doi: 10.23736/S0390-5616.20.04943-7. Epub ahead of print. PMID: 32550606.
17. Pierconti F, **Martini M**, Cenci T, Fiorentino V, Sacco E, Bientinesi R, Pugliese D, Iacovelli R, Schinzari G, Larocca LM, Bassi PF. Methylation study of the Paris system for reporting urinary (TPS) categories. *J Clin Pathol.* 2021

- Feb;74(2):102-105. doi: 10.1136/jclinpath-2020-206633. Epub 2020 Jun 11. PMID: 32527754.
18. Buccarelli M, Lulli V, Giuliani A, Signore M, **Martini M**, D'Alessandris QG, Giannetti S, Novelli A, Ilari R, Giurato G, Boe A, Castellani G, Spartano S, Marangi G, Biffoni M, Genuardi M, Pallini R, Marziali G, Ricci-Vitiani L. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. *Neuro Oncol.* 2020 Dec 18;22(12):1771-1784. doi: 0.1093/neuonc/noaa127. PMID: 32459347; PMCID: PMC7746944.
 19. Brai A, Riva V, Saladini F, Zamperini C, Trivisani CI, Garbelli A, Pennisi C, Giannini A, Boccutto A, Bugli F, **Martini M**, Sanguinetti M, Zazzi M, Dreassi E, Botta M, Maga G. DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins. *Eur J Med Chem.* 2020 Aug 15;200:112319. doi: 10.1016/j.ejmech.2020.112319. Epub 2020 May 7. PMID: 32446036.
 20. Lulli V, Buccarelli M, Ilari R, Castellani G, De Dominicis C, Di Giamberardino A, D'Alessandris QG, Giannetti S, **Martini M**, Stumpo V, Boe A, De Luca G, Biffoni M, Marziali G, Pallini R, Ricci-Vitiani L. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1. *Int J Mol Sci.* 2020 May 20;21(10):3610. doi: 0.3390/ijms21103610. PMID: 32443824; PMCID: PMC7279259.
 21. Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, **Martini M**, Tortora G, Ugel S, Corbo V, Melisi D, Carbone C. Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. *Front Cell Dev Biol.* 2020 Apr 28;8:308. doi: 10.3389/fcell.2020.00308. PMID: 32411709; PMCID: PMC7198708.
 22. Fioravanzo A, Caffo M, Di Bonaventura R, Gardiman MP, Ghimenton C, Ius T, Maffei V, **Martini M**, Nicolato A, Pallini R, Pegolo E, Pinna G, Sala F, Skrap M, Volpin V, Barresi V. A Risk Score Based on 5 Clinico-Pathological Variables Predicts Recurrence of Atypical Meningiomas. *J Neuropathol Exp Neurol.* 2020 May 1;79(5):500-507. doi: 10.1093/jnen/nlaa018. PMID: 32232472.
 23. Strippoli A, Cocomazzi A, Basso M, Cenci T, Ricci R, Pierconti F, Cassano A, Fiorentino V, Barone C, Bria E, Ricci-Vitiani L, Tortora G, Larocca LM, **Martini M**. c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. *Cancers (Basel).* 2020 Mar 10;12(3):638. doi: 10.3390/cancers12030638. PMID: 32164324; PMCID: PMC7139615.
 24. Pierconti F, Raspollini MR, **Martini M**, Larocca LM, Bassi PF, Bientinesi R, Baroni G, Minervini A, Petracco G, Pini GM, Patriarca C. Correction to: PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. *Virchows Arch.* 2020 Aug;477(2):327. doi: 10.1007/s00428-020-02791-y. Erratum for: *Virchows Arch.* 2020 Aug;477(2):269-277. PMID: 32157466.
 25. Dell'Aquila M, Granitto A, **Martini M**, Capodimonti S, Cocomazzi A, Musarra T, Fiorentino V, Pontecorvi A, Lombardi CP, Fadda G, Pantanowitz L, Larocca LM, Rossi ED. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker. *Cancer Cytopathol.* 2020 Mar;128(3):177-189. doi: 10.1002/cncy.22224. Epub 2019 Dec 10. PMID: 31821747.
 26. Iacovelli R, Ciccarese C, Schinzari G, Rossi E, Maiorano BA, Astore S, D'Angelo T, Cannella A, Pirozzoli C, Teberio MA, Pierconti F, **Martini M**, Tortora G. Biomarkers of response to advanced prostate cancer therapy. *Expert Rev Mol Diagn.* 2020 Jan 27;1-11. doi: 10.1080/14737159.2020.1707669.
 27. Maiolo E, Alma E, Napodano C, Gulli F, Bellesi S, Cuccaro A, Pocino K, D'Alo' F, Iachini M, **Martini M**, Larocca LM, De Stefano V, Basile U, Hohaus S. The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). *Leuk Lymphoma.* 2019 Dec 31:1-7. doi: 10.1080/10428194.2019.1706731.
 28. Pacioni S, D'Alessandris QG, Buccarelli M, Boe A, **Martini M**, Larocca LM, Bolasco G, Ricci-Vitiani L, Falchetti ML, Pallini R. Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood-Brain Barrier. *Cancers (Basel).* 2019 Dec 19;12(1). pii: E18. doi: 10.3390/cancers12010018.
 29. Straccia P, **Martini M**, Sacco E, Bassi PF, Pierconti F. Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. *Diagn Cytopathol.* 2020 Feb;48(2):111-117. doi: 10.1002/dc.24331. Epub 2019 Oct 24.
 30. Grande G, Milardi D, **Martini M**, Cenci T, Gulino G, Mancini F, Bianchi A, Pontecorvi A, Pierconti F. Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. *Front Endocrinol (Lausanne).* 2019 Sep 11;10:619. doi: 10.3389/fendo.2019.00619. eCollection 2019.
 31. Pierconti F, **Martini M**, Grande G, Larocca LM, Sacco E, Pugliese D, Gulino G, Bassi PF, Milardi D, Pontecorvi A. Germ Cell Neoplasia in situ (GCNIS) in Testis-Sparing Surgery (TSS) for Small Testicular Masses (STMs). *Front Endocrinol (Lausanne).* 2019 Aug 7;10:512. doi: 10.3389/fendo.2019.00512. eCollection 2019.
 32. Fiorentino V, Pierconti F, Lenci N, Calicchia M, Palermo G, Bassi P, Larocca LM, **Martini M**. Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report. *BMC Cancer.* 2019; 19(1):763.
 33. Silvestris DA, Picardi E, Cesarini V, Fosso B, Mangraviti N, Massimi L, **Martini M**, Pesole G, Locatelli F, Gallo A. Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. *Genome Biol.* 2019 Feb 13;20(1):33.
 34. Chilofo S, Capoluongo ED, Schinzari G, Concolino P, Rossi E, **Martini M**, Cocomazzi A, Grande G, Milardi D, Maiorano BA, Giampietro A, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. *Front Endocrinol (Lausanne).* 2019 Jun 12;10:365
 35. Ricci R, **Martini M**, Ravegnini G, Cenci T, Milione M, Lanza P, Pierconti F, Santini D, Angelini S, Biondi A, Rosa F, Alfieri S, Clemente G, Persiani R, Cassano A, Pantaleo MA, Larocca LM. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. *Clin*

Epigenetics. 2019 Jan 7;11(1):2.

36. Porcu C, Sideri S, **Martini M**, Cocomazzi A, Galli A, Tarantino G, Balsano C. Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. *Int J Mol Sci*. 2018 Dec 8;19(12).
37. Falchetti ML, D'Alessandris QG, Pacioni S, Buccarelli M, Morgante L, Giannetti S, Lulli V, **Martini M**, Larocca LM, Vakana E, Stancato L, Ricci-Vitiani L, Pallini R. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. *Int J Cancer*. 2019 Mar 15;144(6):1331-1344.
38. D'Alessandris QG, Montano N, **Martini M**, Cenci T, Lauretti L, Stumpo V, Pignotti F, Olivi A, Fernandez E, Larocca LM, Pallini R. Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. *Acta Neurochir (Wien)*. 2018 Dec;160(12):2387-2391.
39. Magnini D, Fuso L, Varone F, D'Argento E, **Martini M**, Pecoriello A, Di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L. Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. *Mol Diagn Ther*. 2018 Dec;22(6):723-728.
40. Pierconti F, **Martini M**, Straccia P, Fiorentino V, Musarra T, Larocca LM, Lopez-Beltran A. Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. *APMIS*. 2018 Sep;126(9):705-709.
41. Buccarelli M, Marconi M, Pacioni S, De Pascalis I, D'Alessandris QG, **Martini M**, Ascione B, Malorni W, Larocca LM, Pallini R, Ricci-Vitiani L, Matarrese P. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. *Cell Death Dis*. 2018 Aug 6;9(8):841.
42. **Martini M**, de Pascalis I, D'Alessandris QG, Fiorentino V, Pierconti F, Marei HE, Ricci-Vitiani L, Pallini R, Larocca LM. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. *BMC Cancer*. 2018 May 10;18(1):553.
43. Rossi ED, **Martini M**, Capodimonti S, Cenci T, Bilotta M, Pierconti F, Pontecorvi A, Lombardi CP, Fadda G, Larocca LM. Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules. *Cytopathology*. 2018 Oct;29(5):418-427.
44. Inno A, Di Noia V, **Martini M**, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. *Pathol Oncol Res*. 2018 Mar 20.
45. Porcu C, Antonucci L, Barbaro B, Illi B, Nasi S, **Martini M**, Licata A, Miele L, Grieco A, Balsano C. Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. *Oncotarget*. 2018 Jan 20;9(10):9325-9343.
46. **Martini M**, Capodimonti S, Cenci T, Bilotta M, Fadda G, Larocca LM, Rossi ED. To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniques-The Useful Role of Liquid-Based Cytology. *Arch Pathol Lab Med*. 2018 Mar;142(3):299-307.
47. Spina V, Bruscazzin A, Cuccaro A, **Martini M**, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. *Blood*. 2018 May 31;131(22):2413-2425.
48. De Pascalis I, Morgante L, Pacioni S, D'Alessandris QG, Giannetti S, **Martini M**, Ricci-Vitiani L, Malinverno M, Dejana E, Larocca LM, Roberto Pallini R. Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. *Mod Pathol*. 2018 Sep;31(9):1361-1366.
49. Pierconti F, Rossi ED, **Martini M**, Sacco E, Bassi PF, Larocca LM. 34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. *Appl Immunohistochem Mol Morphol*. 2018 (In press)
50. Servidei T, Meco D, Muto V, Bruxelles A, Cioffi A, Trivieri N, Lucchini M, Morosetti R, Mirabella M, **Martini M**, Caldarelli M, Lasorella A, Tartaglia M, Riccardi R. Novel SEC61G-EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens. *Cancer Res* 2017 (In press)
51. Rossi ED, Mehrotra S, Kilic AI, Toslak IE, Lim-Dunham J, **Martini M**, Fadda G, Lombardi CP, Larocca LM, Barkan GA. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group. *Cancer*. 2017 (In press)
52. De Stefano A, Rosanova M, Malapelle U, **Martini M**, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C. Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? *Int J Biol Markers*. 2017 (In press)
53. Rossi ED*, **Martini M***, Larocca LM*. When Somatic Mutations Are Associated With a Higher Aggressive Behavior-A Story of Announced Evidence. *JAMA Oncol*. 2017 Oct 1;3(10):1427-1428.
54. Rossi ED, **Martini M**, Cenci T, Capodimonti S, Larocca LM. The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature. *Cancer*. 2017 Aug;125(8):594-603.
55. Rossi ED, **Martini M**. New Insight in a New Entity: NIFTPS and Valuable Role of Ancillary Techniques. The Role of PD-L1. *EBioMedicine*. 2017 Apr;18:11-12. IF. 1.923
56. Rossi S, Congedo T, Ricci R, **Martini M**, Di Noia V, Di Dio C, Quirino M, Barone C, Cassano A. Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. *J Gastrointest Oncol*. 2017 Feb;8(1):E4-E9.
57. Marziali G, Buccarelli M, Giuliani A, Ilari R, Grande S, Palma A, D'Alessandris QG, **Martini M**, Biffoni M, Pallini R, Ricci-Vitiani L. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical

- outcomes. *Mol Oncol*. 2017 Sep;11(9):1115-1129.
58. Pierconti F, **Martini M**, Cenci T, Petrone GL, Ricci R, Sacco E, Bassi PF, Larocca LM. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. *Prostate*. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1. PubMed PMID: 28144985.
 59. Willmann JK, Bonomo L, Testa A, Rinaldi P, Rindi G, Valluru KS, Petrone G, **Martini M**, Lutz AM, Gambhir SS. Ultrasound Molecular Imaging in Patients with Breast and Ovarian Lesions: First-In-Human Results. *Journal of Clinical Oncology*, 2016, (In press).
 60. D'Alessandris QG,* Biffoni M,* **Martini M**,* Signore M, Stancato L, Ricci Vitiani L, Larocca LM, Pallini R. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. *Neuro-Oncology*, 2016, (In press). IF. 7.371
 61. Cesarini V,* **Martini M**,* Ricci Vitiani L, Gravina GL, Di Agostino S, Graziani G, D'Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini ES, Dolci S. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. *Oncotarget*, 2016, (In press). IF. 5.008
 62. Rossi ED, Bizzarro T, **Martini M**, Larocca LM, Schmitt F, Vielh P. Cytopathology of Follicular Cell Nodules. *Adv Anat Pathol*. 2017 Jan;24(1):45-55.
 63. Pierconti F, **Martini M**, Cenci T, Larocca LM. The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior. *Appl Immunohistochem Mol Morphol*. 2016 Oct 31
 64. Rossi ED,* **Martini M**,* Bizzarro T, Schmitt F, Longatto-Filho A, Larocca LM. Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. *Oncotarget*. 2016 Oct 11 (In press). IF. 5.008
 65. Bizzarro T, **Martini M**, Capodimonti S, Straccia P, Lombardi CP, Pontecorvi A, Larocca LM, Rossi ED. Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification. *Cancer*. 2016 Oct;124(10):699-710.
 66. Rodriquenz MG, Rossi S, Ricci R, **Martini M**, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D'Argento E, Strippoli A, Barone C, Cassano A. Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel "sentinel tumor"? A monoinstitutional, STROBE-compliant observational analysis. *Medicine (Baltimore)*. 2016 Sep;95(38):e4718.
 67. Quero G, Musarra T, Carrato A, Fici M, **Martini M**, Dei Tos AP, Alfieri S, Ricci R. Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature. *Medicine (Baltimore)*. 2016 Jul;95(28):e4207.
 68. Rossi ED, Bizzarro T, Granja S, **Martini M**, Capodimonti S, Luca E, Fadda G, Lombardi CP, Pontecorvi A, Larocca LM, Baltazar F, Schmitt F. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation. *Endocrine*. 2016 Aug 2 (In press).
 69. Ricci R, **Martini M**, Cenci T, Riccioni ME, Maria G, Cassano A, Larocca LM. Divergent gastrointestinal stromal tumors in syndromic settings. *Cancer Genet*. 2016 Jul-Aug;209(7-8):354-8.
 70. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM. Morphological features that can predict BRAFV600E -mutated carcinoma in paediatric thyroid cytology. *Cytopathology*. 2016 Jun 3 (In press).
 71. Strippoli A, Rossi S, **Martini M**, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. *Oncotarget*. 2016 Jun 7;7(23):35159-68.
 72. Flex A, Biscetti F, Iachininoto MG, Nuzzolo ER, Orlando N, Capodimonti S, Angelini F, Valentini CG, Bianchi M, Larocca LM, **Martini M**,* Teofilii L.* Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. *Thromb Res*. 2016 May;141:106-11. IF. 2.32
 73. Rossi ED, Bizzarro T, **Martini M**, Straccia P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. The role of fine-needle aspiration in the thyroid nodules of elderly patients. *Oncotarget*. 2016 Mar 15;7(11):11850-9.
 74. Marziali G, Signore M, Buccarelli M, Grande S, Palma A, Biffoni M, Rosi A, D'Alessandris QG, **Martini M**, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. *Sci Rep*. 2016 Feb 9;6:21557.
 75. Bravi L, Malinverno M, Pisati F, Rudini N, Cuttano R, Pallini R, **Martini M**, Larocca LM, Locatelli M, Levi V, Bertani GA, Dejana E, Lampugnani MG. Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. *Stroke*. 2016 Mar;47(3):886-90.
 76. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Sarti D, Cenci T, Bilotta M, Fadda G, Larocca LM. The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms. *Endocrine*. 2016 Dec;54(3):723-732.
 77. Cuccaro A, Annunziata S, Cupelli E, **Martini M**, Calcagni ML, Rufini V, Giachella M, Bartolomei F, Galli E, D'Alò F, Voso MT, Leone G, Giordano A, Larocca LM, Hohaus S. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. *Cancer Med*. 2016 Mar;5(3):398-406.
 78. Orlandi A, Calegari MA, **Martini M**, Cocomazzi A, Bagalà C, Indelicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. *Clin Transl Oncol*. 2016 Oct;18(10):988-95
 79. Rossi S, D'Argento E, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, **Martini M**, Cassano A, Barone C. Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. *Mol Diagn Ther*. 2016 Feb;20(1):55-63.

80. **Martini M**, Capodimonti S, Iachininoto MG, Cocomazzi A, Nuzzolo ER, Voso MT, Teofili L, Larocca LM. An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. *Blood Cancer J*. 2015 Nov 27;5:e370. IF. 4.411
81. Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, **Martini M**, Barone C. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. *Mol Diagn Ther*. 2016 Feb;20(1):65-74.
82. Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachelia M, **Martini M**, Beilesi S, D'Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2016;57(3):628-34.
83. Rizzo D, Ruggiero A, **Martini M**, Rizzo V, Maurizi P, Riccardi R. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. *Biomed Res Int*. 2015;2015:215135.
84. Lulli V, Buccarelli M, **Martini M**, Signore M, Biffoni M, Giannetti S, Morgante L, Marziali G, Ilari R, Pagliuca A, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. *Oncotarget*. 2015 Nov 10;6(35):37241-56.
85. Rossi ED, ***Martini M***, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights. *Cancer Cytopathol*. 2015 Oct;123(10):593-602. IF. 3.092
86. Bizzarro T, Martini M, Marrocco C, D'Amato D, Traini E, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM, Rossi ED. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology. *PLoS One*. 2015 Jul 17;10(7):e0132939.
87. Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, **Martini M**, Li Zhang S, Santangelo R, Larocca LM, Criscuolo M, La Brocca A, Cutcutache I, Rozen S, Simonetti G, Manfrini M, Martinelli G, Hohaus S, Leone G, Tan P, Tenen DG. Fanconi anemia gene variants in therapy-related myeloid neoplasms. *Blood Cancer J*. 2015 Jul 3;5:e323.
88. Teofili L, ***Martini M***, Nuzzolo ER, Capodimonti S, Iachininoto MG, Cocomazzi A, Fabiani E, Voso MT, Larocca LM. Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia. *Neoplasia*. 2015 May;17(5):401-9. IF. 5.476
89. Ricci R, **Martini M**, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. *Mod Pathol*. 2015 Jul;28(7):954-64.
90. Puglisi MA, Cenciarelli C, Tesori V, Cappellari M, **Martini M**, Di Francesco AM, Giorda E, Carsetti R, Ricci-Vitiani L, Gasbarrini A. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. *J Pathol*. 2015 Aug;236(4):479-90.
91. D'Alessandris QG, **Martini M**, Cenci T, Capo G, Ricci-Vitiani L, Larocca LM, Pallini R. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. *Neurology*. 2015 May 5;84(18):1906-8.
92. Ricci R, Chiarello G, Atili F, Fuccio L, Alfieri S, Persiani R, Di Pietro S, **Martini M**, Costamagna G, Larocca LM, Larghi A. Endoscopic ultrasound-guided fine needle tissue acquisition biopsy samples do not allow a reliable proliferation assessment of gastrointestinal stromal tumours. *Dig Liver Dis*. 2015 Apr;47(4):291-5.
93. Rossi ED, **Martini M**, Straccia P, Bizzarro T, Fadda G, Larocca LM. The potential of liquid-based cytology in lymph node cytological evaluation: the role of morphology and the aid of ancillary techniques. *Cytopathology*. 2016 Feb;27(1):50-8. doi: 10.1111/cyt.12229.
94. Rossi ED, **Martini M**, Straccia P, Gerhard R, Evangelista A, Pontecorvi A, Fadda G, Maria Larocca L, Schmitt F. Is thyroid gland only a "land" for primary malignancies? role of morphology and immunocytochemistry. *Diagn Cytopathol*. 2015 May;43(5):374-80.
95. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Fadda G, Larocca LM, Schmitt F. Morphological parameters able to predict BRAFV600E -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. *Cancer Cytopathol*. 2014 Dec;122(12):883-91.
96. Ricci R, **Martini M**, Cenci T, Antinori A, Cassano A, Larocca LM. Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive. *J Clin Oncol*. 2016 Apr 20;34(12):e107-9.
97. Rossi ED, **Martini M**, Capodimonti S, Straccia P, Revelli L, Lombardi CP, Pontecorvi A, Santeusano G, Larocca LM, Fadda G. Well-differentiated Thyroid Cancer With a Minor Poorly Differentiated Component: Clonal Heterogeneity Through the Prognostic Role of CXCR4 and BRAF Analysis. *Appl Immunohistochem Mol Morphol*. 2015 Mar;23(3):196-201.
98. Giona F, Teofili L, Capodimonti S, Laurino M, **Martini M**, Marzella D, Palumbo G, Diverio D, Foà R, Larocca LM. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. *Blood*. 2014 Jun 5;123(23):3677-9.
99. Giachelia M, Bozzoi V, D'Alò F, Tisi MC, Massini G, Maiolo E, Guidi F, Cupelli E, **Martini M**, Larocca LM, Voso MT, Leone G, Hohaus S. Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. *J Mol Diagn*. 2014 Jul;16(4):467-76.
100. Natalicchio MI, Improta G, Zupa A, Cursio OE, Stampone E, Possidente L, Teresa Gerardi AM, Vita G, **Martini M**, Cassano A, Piccoli C, Romito S, Aieta M, Antonetti R, Barone C, Landriscina M. Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. *Future Oncol*. 2014 Apr;10(5):713-23.
101. Rossi ED, **Martini M**, Straccia P, Cocomazzi A, Pennacchia I, Revelli L, Rossi A, Lombardi CP, Larocca LM, Fadda G. Thyroglossal duct cyst cancer most likely arises from a thyroid gland remnant. *Virchows Arch*. 2014 Jul;465(1):67-72.

102. Pierconti F, Milardi D, **Martini M**, Grande G, Cenci T, Gulino G, Larocca LM, Rindi G, Pontecorvi A, De Marinis L. Pituitary-tumour-transforming-gene 1 expression in testicular cancer. *Andrologia*. 2015 May;47(4):427-32.
103. Rossi ED*, **Martini M***, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience. *Cancer Cytopathol*. 2014 Jul;122(7):527-35. IF. 3.092
104. Rossi ED, **Martini M**, Fadda G, Larocca LM. Papillary thyroid microcarcinoma: a painstaking category to manage. *Clin Endocrinol (Oxf)*. 2014 Nov;81(5):785-6.
105. Rossi ED, Straccia P, **Martini M**, Revelli L, Lombardi CP, Pontecorvi A, Fadda G. The role of thyroid fine-needle aspiration cytology in the pediatric population: an institutional experience. *Cancer Cytopathol*. 2014 May;122(5):359-67.
106. Di Bella S, Taglietti F, Cicalini S, Baiocchini A, **Martini M**, Galluccio G, Gouliouris T, Petrosillo N. Photoquizz. Holoinspiratory wheezing in a 46-year-old HIV-seropositive man. *Clin Infect Dis*. 2014 Jan;58(1):78, 134-5.
107. Rossi ED, **Martini M**, Straccia P, Raffaelli M, Pennacchia I, Marrucci E, Lombardi CP, Pontecorvi A, Fadda G. The cytologic category of oncocytic (Hurthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience. *Eur J Endocrinol*. 2013 Oct 1;169(5):649-55.
108. Nuzzolo ER, Capodimonti S, **Martini M**, Iachinoto MG, Bianchi M, Cocomazzi A, Zini G, Leone G, Larocca LM, Teofili L. Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. *Blood Transfus*. 2014 Jan;12 Suppl 1:s367-74.
109. Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, **Martini M**, Bianchi F, Maira G, Stancato L, De Maria R, Larocca LM, Pallini R. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. *Neoplasia*. 2013 Jul;15(7):773-82.
110. **Martini M**, Santoro L, Familiari P, Costamagna G, Ricci R. Inflammatory fibroid polyp of the gallbladder bearing a platelet-derived growth factor receptor alpha mutation. *Arch Pathol Lab Med*. 2013 May;137(5):721-4. IF. 2.631
111. Lauriola L, Serini S, Granone P, Lanza P, **Martini M**, Calviello G, Ranelletti FO. Hu/elav RNA-binding protein HuR regulates parathyroid hormone related peptide expression in human lung adenocarcinoma cells. *Histol Histopathol*. 2013 Sep;28(9):1205-16.
112. Rossi ED, **Martini M**, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. *Eur J Endocrinol*. 2013 May 2;168(6):853-9.
113. Bussu F, Hohaus S, Bastanza G, Bozzoli V, Tisi MC, **Martini M**, Paludetti G, Almadori G. Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients. *Clin Otolaryngol*. 2013 Jun;38(3):248-53.
114. Vecchiet J, Iachinoto MG, Capodimonti S, Nuzzolo ER, Falasca K, **Martini M**, Mancino P, Bianchi M, Leone AM, Ucciferri C, Larocca LM, Teofili L. Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. *Thromb Res*. 2013 Mar;131(3):238-43.
115. Novello M, Coli A, Della Pepa GM, **Martini M**, Doglietto F, De Stefano V, Bellesi S, Pescarmona E, Lauriola L. (in stampa). Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor. *Neuropathology*. 2014 Apr;34(2):179-84.
116. Rossi ED, **Martini M**, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. *Cancer Cytopathol*. 2013 Jun;121(6):291-7.
117. Rossi ED, **Martini M**, Straccia P, Larocca LM, Fadda G. Detection of ectopic thyroid remnants: a serious diagnostic dilemma. When molecular biology and immunohistochemistry can solve the problem. *Pathol Res Pract*. 2013 Jan 15;209(1):59-61.
118. Basso M, Strippoli A, Orlandi A, **Martini M**, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C. KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. *Br J Cancer*. 2013 Jan 15;108(1):115-20.
119. Falasca K, Ucciferri C, Teofili L, Iachinoto M, Capodimonti S, Nuzzolo ER, Bianchi M, **Martini M**, Vignale F, Pizzigallo E, Vecchiet J. Proangiogenic hematopoietic cells in acute HIV infection. *AIDS Res Hum Retroviruses*. 2013 Feb;29(2):307-10.
120. Teofili L, Nuzzolo ER, Vecchiet J, Falasca K, Iachinoto MG, **Martini M**, Larocca LM. Endothelial progenitor cells in HIV-positive patients: what are we talking about? *J Acquir Immune Defic Syndr*. 2013 Jan 1;62(1):e22-3.
121. **Martini M**, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R, Larocca LM. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. *Cancer*. 2013 Mar 1;119(5):1004-12. IF. 5.649
122. D'Alessandris QG, Montano N, Cenci T, **Martini M**, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. *Acta Neurochir (Wien)*. 2013 Jan;155(1):33-40.
123. Rossi ED, Revelli L, **Martini M**, Taddei A, Pintus C, Panunzi C, Fadda G. Cribriform-Morular Variant of Papillary Thyroid Carcinoma in an 8-Year-Old Girl: A Case Report With Immunohistochemical and Molecular Testing. *Int J Surg Pathol*. 2012 Dec;20(6):629-32.
124. de Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscazzin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, **Martini M**, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D. MGA, A Suppressor of MYC, is Recurrently Inactivated in High Risk Chronic Lymphocytic Leukemia. *Leuk Lymphoma*. 2013

125. Serio G, Zampatti C, Ballabio A, Ricci R, **Martini M**, Zurleni F. Neurofibromatosis 1 presenting with multiple duodenal GISTS associated with a somatostatin-producing D cell neoplasm. *Endocr Pathol.* 2013 Jun;24(2):100-5.
126. Cianci R, Cammarota G, Frisullo G, Pagliari D, Ianiro G, **Martini M**, Frosali S, Plantone D, Damato V, Casciano F, Landolfi R, Paola Batocchi A, Pandolfi F. Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. *Clin Transl Gastroenterol.* 2012 Dec 13;3:e28.
127. Strisciuglio C, Corleto VD, Brunetti-Pierri N, Piccolo P, Sangermano R, Rindi G, **Martini M**, D'Armiento FP, Staiano A, Miele E. Autosomal dominant Ménétrier-like disease. *J Pediatr Gastroenterol Nutr.* 2012 Dec;55(6):717-20.
128. Capello D, Gloghini A, Baldanzi G, **Martini M**, Deambrogi C, Lucioni M, Piranda D, Famà R, Graziani A, Spina M, Tirelli U, Paulli M, Larocca LM, Gaidano G, Carbone A, Sinigaglia F. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. *Hematol Oncol.* 2013 Mar;31(1):22-8.
129. Cenci T, **Martini M**, Montano N, D'Alessandris QG, Falchetti ML, Annibali D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. *Am J Clin Pathol.* 2012 Sep;138(3):390-6.
130. Rossi ED, **Martini M**, Cingolani N, Ranaldi R, Fadda G. Images in endocrine pathology: spindle cell lesion of the thyroid gland. *Endocr Pathol.* 2012 Jun;23(2):132-4.
131. Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Brusca A, Laurenti L, **Martini M**, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. *Br J Haematol.* 2012 Aug;158(3):426-9.
132. Leuzzi G, Cesario A, Vita ML, Parisi AM, Petrone G, **Martini M**, Rindi G, Granone P. Difference in clonality as a tool for differential diagnosis of primary versus secondary lung neoplasms. *J Thorac Oncol.* 2012 May;7(5):934-6.
133. Capodimonti S, Teofili L, **Martini M**, Cenci T, Iachininoto MG, Nuzzolo ER, Bianchi M, Murdolo M, Leone G, and Larocca LM. von Hippel Lindau disease and erythrocytosis. *J Clin Oncol.* 2012 May 1;30(13):e137-9.
134. Giona F, Teofili L, Moleti ML, **Martini M**, Palumbo G, Amendola A, Mazzucconi MG, Testi AM, Pignoloni P, Orlando SM, Capodimonti S, Nanni M, Leone G, Larocca LM, Foà R. Thrombocytopenia and polycythemia in patients younger than 20 years at diagnosis: clinical and biological features, treatment, and long-term outcome. *Blood.* 2012 Mar 8;119(10):2219-27.
135. Montano N*, Cenci T*, **Martini M***, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R. Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. *Neoplasia.* 2011 Dec;13(12):1113-21. IF. 5.476
136. Giachella M, Voso MT, Tisi MC, **Martini M**, Bozzoli V, Massini G, D'Alò F, Larocca LM, Leone G, Hohaus S. Interleukin-6 plasma levels are modulated by a polymorphism in the NF- κ B1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. *Leuk Lymphoma.* 2012 Mar;53(3):411-6.
137. Rossi D, Spina V, Forconi F, Capello D, Fangazio M, Rasi S, **Martini M**, Gattei V, Ramponi A, Larocca LM, Bertoni F, Gaidano G. Molecular history of richter syndrome: Origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. *Int J Cancer.* 2012 Jun 15;130(12):3006-10.
138. **Martini M**, Ferrara AM, Giachella M, Panieri E, Siminovitch K, Galeotti T, Larocca LM, Pani G. Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. *Inflamm Bowel Dis.* 2012 Mar;18(3):439-48. IF. 4.358
139. Inno A, Di Salvatore M, Cenci T, **Martini M**, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? *Clin Colorectal Cancer.* 2011 Dec;10(4):325-32.
140. Hohaus S, Santangelo R, Giachella M, Vannata B, Massini G, Cuccaro A, **Martini M**, Cesarini V, Cenci T, D'Alò F, Voso MT, Fadda G, Leone G, Larocca LM. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. *Clin Cancer Res.* 2011 May 1;17(9):2885-92.
141. Capello D, Gloghini A, **Martini M**, Spina M, Tirelli U, Bertoni F, Rinaldi A, Morra E, Rimbaldi A, Sinigaglia F, Larocca LM, Carbone A. Mutations of CD79a, CD79b and EZH2 genes in immunodeficiency-related non-hodgkin lymphomas. *Br J Haematol.* 2011 Mar;152(6):777-80.
142. Teofili L*, **Martini M***, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. *Blood.* 2011 Mar 3;117(9):2700-7. IF. 11.841
143. Rossi ED, Larghi A, Verna EC, **Martini M**, Galasso D, Carnuccio A, Larocca LM, Costamagna G, Fadda G. Endoscopic ultrasound-guided fine-needle aspiration with liquid-based cytologic preparation in the diagnosis of primary pancreatic lymphoma. *Pancreas.* 2010 Nov;39(8):1299-302.
144. Teofili L, Iachininoto MG, Capodimonti S, Ucciferri C, Nuzzolo ER, **Martini M**, Torti L, Falasca K, Vecchiet J, Leone G, Larocca LM. Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. *AIDS.* 2010 Oct 23;24:2443-50.
145. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, **Martini M**, De Maria R, Larocca LM. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. *Cancer.* 2011 Jan 1;117(1):162-74.
146. Pierconti F*, **Martini M***, Pinto F, Cenci T, Capodimonti S, Calarco A, Bassi PF, Larocca LM. Epigenetic silencing of

- SOCS3 identifies a subset of prostate cancer with an aggressive behavior. *Prostate*. 2011 Feb 15;71(3):318-25. IF. 3.778
147. Teofili L, Giona F, **Martini M**, Torti L, Cenci T, Foà R, Leone G, and Larocca LM. MPL activation, thrombopoietin mimetic drugs and hereditary thrombocytosis: remarks on bone marrow fibrosis. *J Clin Oncol*. 2010 Jul 1;28(19):e317-8.
 148. Capello D, Scandurra M, Poretti G, Rancoita PMV, Mian M, Gloghini A, Deambrogi C, **Martini M**, Rossi D, Greiner TC, Chan WC, Ponzoni M, Montes Moreno S, Piris MA, Canzonieri V, Spina M, Tirelli U, Inghirami G, Rinaldi A, Zucca E, Dalla Favera R, Cavalli F, Larocca LM, Kwee I, Carbone A, Gaidano G, Bertoni F. Genome wide DNA-profiling of HIV-related B-cell lymphomas. *Br J Haematol*. 2010 Jan;148(2):245-55.
 149. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, Nunes V, Foà R, Leone G, **Martini M**, Larocca LM. MPLSer505Asn induced hereditary thrombocytosis is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. *Haematologica*. 2010 Jan;95(1):65-70.
 150. Liu K, **Martini M**, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC. *Haematologica*. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. *Haematologica*. 2009 Oct;94(10):1368-74.
 151. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, **Martini M**, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome. *Clin Cancer Res*. 2009 Jul 1;15(13):4415-22.
 152. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, **Martini M**, Larocca LM, Voso MT, Leone G. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. *Ann Oncol*. 2009 Aug;20(8):1408-13.
 153. Lucantoni C, De Bonis P, Doglietto F, Esposito G, Larocca LM, Mangiola A, **Martini M**, Papacci F, Teofili L, Pompucci A. Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. *J Neurooncol*. 2009 Sep;94(2):235-42.
 154. Hohaus S, Giachelia M, Massini G, Vannata B, Criscuolo M, **Martini M**, D'Alo' F, Voso MT, Larocca LM, Leone G. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. *Leuk Res*. 2009 Oct;33(10):1352-6.
 155. Teofili L, Cenci T, **Martini M**, Capodimonti S, Torti L, Giona F, Amendola A, Randi ML, Putti MC, Scapin M, Leone G, Larocca LM. The mutant JAK2V617F allele burden in children with essential thrombocythemia. *Br J Haematol*. 2009 May;145(3):430-2.
 156. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, **Martini M**, Maira G, Larocca LM, De Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. *Clin Cancer Res*. 2008 Dec 15;14(24):8205-12.
 157. Marotta D, Sgambato A, Cerciello S, Magarelli N, **Martini M**, Larocca LM, Maccauro G. Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. *World J Surg Oncol*. 2008 Oct 21;6:111.
 158. **Martini M**, Pallini R, Luongo G, Cenci T, Lucantoni C and Larocca LM. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. *Int J Cancer*. 2008 Dec 15;123(12):2955-60. IF. 5.531
 159. Teofili L*, **Martini M***, Cenci T, Guidi F, Torti L, Giona F, Foà R, Leone G, Larocca LM. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. *Int J Cancer*. 2008 Oct 1;123(7):1586-92. IF. 5.531
 160. Capello D, **Martini M**, Gloghini A, Cerri M, Rasi S, Deambrogi C, Rossi D, Spina M, Tirelli U, Larocca LM, Carbone A, Gaidano G. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. *Haematologica*. 2008 Aug;93(8):1178-85.
 161. **Martini M**, Teofili L, Cenci T, Giona F, Torti L, Rea M, Foà R, Leone G, Larocca LM. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. *Haematologica*. 2008 Jul;93(7):1068-71. IF. 6.671
 162. **Martini M**, Hohaus S, Petrucci G, Cenci T, Pierconti F, Massini G, Teofili L, Leone G, Larocca LM. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. *Am J Clin Pathol*. 2008 Mar;129(3):472-7. IF. 2.278
 163. Reddiconto G, Chiusolo P, Fiorini A, Farina G, Laurenti L, **Martini M**, Marchetti S, Fadda G, Leone G, Sica S. Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. *Leukemia*. 2007 Dec;21(12):2552-4.
 164. Teofili L, Giona F, **Martini M**, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foa R, Larocca LM. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. *Blood* 2007 Nov;19(11):1026-30.
 165. Miele L, Pierconti F, Forgione A, Vero V, Cammarota G, Molinari F, Masselli G, Capristo E, **Martini M**, LM Larocca, Civello IM, Gasbarrini G, Grieco A. Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. *Eur. J. Gastroenterol Hepatol*. 2007 Nov;19(11):1026-30.
 166. Hohaus S, Giachelia M, Di Febo A, **Martini M**, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G. Polymorphism in cytokine genes as prognostic markers in Hodgkin lymphoma. *Ann Oncol*.

2007 Aug;18(8):1376-81.


167. Teofili L, **Martini M**, Cenci T, Petrucci G, Torti L, Storti S, Guidi F, Leone G, Larocca LM. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. *Blood*. 2007 Jul 1;110(1):354-9.
168. Hohaus S, Mansueto G, Massini G, D'Alo' F, Giachella M, **Martini M**, Larocca LM, Voso MT, Leone G. Glutathione-S-Transferase (GST) genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. *Leuk Lymphoma*, March 2007; 48(3): 564 – 569. (
169. Teofili L, Giona F, **Martini M**, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foa R, Larocca LM. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. *J Clin Oncol*. 2007 Mar 20;25(9):1048-53.
170. Scardocci A, Guidi F, D'Alo' F, Gumiero D, Fabiani E, Diruscio A, **Martini M**, Larocca LM, Zollino M, Hohaus S, Leone G, Voso MT. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. *Br J Cancer*. 2006 Oct 23;95(8):1108-13.
171. Voso MT, Gumiero D, D'Alo' F, Guidi F, Mansueto G, Di Febo AL, Massini G, **Martini M**, Larocca LM, Hohaus S, Leone G. DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. *Haematologica*. 2006 Sep;91(9):1252-6.
172. **Martini M**, Capello D, Serraino D, Navarra A, Pierconti F, Cenci T, Gaidano G, Larocca LM. Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. *J Infect*. 2007 Mar;54(3):298-306. IF. 4.832
173. Larocca LM, **Martini M**. Pathology of Epstein-Barr virus-related lymphomas in HIV. *Haematologica*. 2005 Sep;1 (5): 19-20.
174. Teofili L, **Martini M**, Guidi F, Gumiero D, Leone G, Larocca LM. The PRV-1 Gene Expression in Essential Thrombocythemia. *Blood* 2004, Nov 1;104(9):2995-6.
175. Ricci R, Arena V, Castri F, **Martini M**, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in Gastrointestinal Stromal Tumor Progression. *Am J Clin Pathol*. 2004 Jul;122(1):35-43.
176. Arena V, **Martini M**, Luongo M, Capelli A, Larocca LM. Mutations of the BIK gene in human peripheral B-cell lymphomas. *Genes Chromosomes Cancer*. 2003 Sep;38(1):91-6.
177. Teofili L, **Martini M**, Luongo M, Diverio D, Capelli G, Breccia M, Lo Coco F, Leone G, Larocca LM. Hypermethylation of CpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. *Leukemia*. 2003 May;17(5):919-24.
178. **Martini M**, Luongo M, Teofili L, Di Mario A, Leone G, Larocca LM. Dysregulated expression of Bcl-xL in CD34+ cells isolated from patients with refractory anemia with excess of blasts during megakaryocytic differentiation. *Haematologica*. 2002 Dec;87(12):1342-3. IF. 6.671
179. Cammarota G, Cianci R, Grillo RL, **Martini M**, Di Campi C, Pompili M, Pignataro G, Cuoco L, De Lorenzo A, Gasbarrini G, Pandolfi F, Larocca LM. Relationship between gastric localization of hepatitis C virus and mucosa-associated lymphoid tissue in Helicobacter pylori infection. *Scand J Gastroenterol*. 2002 Oct;37(10):1126-32.
180. **Martini M**, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Zannoni G, Vittori G, Larocca LM. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. *Int J Cancer*. 2002 Dec 1;102(4):398-406. IF. 5.531
181. Teofili L*, **Martini M***, Luongo M, Di Mario A, Leone G, De Stefano V, Larocca LM. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. *J Clin Oncol*. 2002 Oct 15;20(20):4249-54. IF. 20.982
182. **Martini M**, D'Alo F, Hohaus S, Leone G, Larocca LM. Absence of structural mutations of the BAK gene in B cell lymphomas. *Haematologica*. 2002 Jun;87(6):661-2. IF. 6.671
183. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, **Martini M**, Barone C. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. *Eur J Cancer*. 2002 Mar;38(4):527-34.
184. Fassone L, Cingolani A, **Martini M**, Migliaretti G, Oreste PL, Capello D, Gloghini A, Vivenza D, Dolcetti R, Carbone A, Antinori A, Gaidano G, Larocca LM. Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. *AIDS Res Hum Retroviruses*. 2002 Jan 1;18(1):19-26.
185. Teofili L, **Martini M**, Di Mario A, Rutella S, Urbano R, Luongo M, Leone G, Larocca LM. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. *Blood*. 2001 Jul 15;98(2):495-7.
186. Ricci R, Maggiano N, **Martini M**, Mule AM, Pierconti F, Capelli A, Larocca LM. Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. *Virchows Arch*. 2001 Feb;438(2):159-65.
187. Falchetti ML, Pallini R, D'Ambrosio E, Pierconti F, **Martini M**, Cimino-Reale G, Verna R, Maira G, Larocca LM. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. *Int J Cancer*. 2000 Dec 15;88(6):895-901.
188. **Martini M**, D'Alo F, Pierconti F, Ricci R, Capelli A, Leone G, Larocca LM. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. *Haematologica*. 2000 Oct;85(10):1019-23. IF. 6.671
189. Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, **Martini M**, De Luca A, Ammassari A, Mazzone C, Pescarmona E, Gaidano G, Larocca LM, Antinori A. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. *J Clin Oncol*. 2000 Oct 1;18(19):3325-30.
190. Teofili L, Morosetti R, **Martini M**, Urbano R, Putzulu R, Rutella S, Pierelli L, Leone G, Larocca LM. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. *Exp Hematol*. 2000 May;28(5):519-26.

Chapter on BOOK

Martini M, Teofili L, Larocca LM. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia. in Methods Mol Med. Myeloid Leukemia: methods and protocols. Eds Lland H., Hertzberg M., Marlton P. Humana Press 2006; pp. 265-73.

***The authors equally contributed or shared the seniorship.**

Rome 15/08/2021.

A handwritten signature in black ink, consisting of several overlapping loops and a long horizontal stroke at the end, positioned to the right of the date.